217 related articles for article (PubMed ID: 32211339)
1. N-Glycans Mediate the Ebola Virus-GP1 Shielding of Ligands to Immune Receptors and Immune Evasion.
Iraqi M; Edri A; Greenshpan Y; Kundu K; Bolel P; Cahana A; Ottolenghi A; Gazit R; Lobel L; Braiman A; Porgador A
Front Cell Infect Microbiol; 2020; 10():48. PubMed ID: 32211339
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive functional analysis of N-linked glycans on Ebola virus GP1.
Lennemann NJ; Rhein BA; Ndungo E; Chandran K; Qiu X; Maury W
mBio; 2014 Jan; 5(1):e00862-13. PubMed ID: 24473128
[TBL] [Abstract][Full Text] [Related]
3. Targeting host O-linked glycan biosynthesis affects Ebola virus replication efficiency and reveals differential GalNAc-T acceptor site preferences on the Ebola virus glycoprotein.
Bagdonaite I; Abdurahman S; Mirandola M; Pasqual D; Frank M; Narimatsu Y; Joshi HJ; Vakhrushev SY; Salata C; Mirazimi A; Wandall HH
J Virol; 2024 Jun; 98(6):e0052424. PubMed ID: 38757972
[TBL] [Abstract][Full Text] [Related]
4. Steric shielding of surface epitopes and impaired immune recognition induced by the ebola virus glycoprotein.
Francica JR; Varela-Rohena A; Medvec A; Plesa G; Riley JL; Bates P
PLoS Pathog; 2010 Sep; 6(9):e1001098. PubMed ID: 20844579
[TBL] [Abstract][Full Text] [Related]
5. MARCH8 Inhibits Ebola Virus Glycoprotein, Human Immunodeficiency Virus Type 1 Envelope Glycoprotein, and Avian Influenza Virus H5N1 Hemagglutinin Maturation.
Yu C; Li S; Zhang X; Khan I; Ahmad I; Zhou Y; Li S; Shi J; Wang Y; Zheng YH
mBio; 2020 Sep; 11(5):. PubMed ID: 32934085
[TBL] [Abstract][Full Text] [Related]
6. Influences of glycosylation on antigenicity, immunogenicity, and protective efficacy of ebola virus GP DNA vaccines.
Dowling W; Thompson E; Badger C; Mellquist JL; Garrison AR; Smith JM; Paragas J; Hogan RJ; Schmaljohn C
J Virol; 2007 Feb; 81(4):1821-37. PubMed ID: 17151111
[TBL] [Abstract][Full Text] [Related]
7. The Tetherin Antagonism of the Ebola Virus Glycoprotein Requires an Intact Receptor-Binding Domain and Can Be Blocked by GP1-Specific Antibodies.
Brinkmann C; Nehlmeier I; Walendy-Gnirß K; Nehls J; González Hernández M; Hoffmann M; Qiu X; Takada A; Schindler M; Pöhlmann S
J Virol; 2016 Dec; 90(24):11075-11086. PubMed ID: 27707924
[TBL] [Abstract][Full Text] [Related]
8. Mucin-Like Domain of Ebola Virus Glycoprotein Enhances Selective Oncolytic Actions against Brain Tumors.
Zhang X; Zhang T; Davis JN; Marzi A; Marchese AM; Robek MD; van den Pol AN
J Virol; 2020 Mar; 94(8):. PubMed ID: 32051271
[TBL] [Abstract][Full Text] [Related]
9. The Role of Conserved N-Linked Glycans on Ebola Virus Glycoprotein 2.
Lennemann NJ; Walkner M; Berkebile AR; Patel N; Maury W
J Infect Dis; 2015 Oct; 212 Suppl 2(Suppl 2):S204-9. PubMed ID: 26038399
[TBL] [Abstract][Full Text] [Related]
10. Enhancement of Ebola Virus Infection via Ficolin-1 Interaction with the Mucin Domain of GP Glycoprotein.
Favier AL; Gout E; Reynard O; Ferraris O; Kleman JP; Volchkov V; Peyrefitte C; Thielens NM
J Virol; 2016 Jun; 90(11):5256-5269. PubMed ID: 26984723
[TBL] [Abstract][Full Text] [Related]
11. Glycan shield of the ebolavirus envelope glycoprotein GP.
Peng W; Rayaprolu V; Parvate AD; Pronker MF; Hui S; Parekh D; Shaffer K; Yu X; Saphire EO; Snijder J
Commun Biol; 2022 Aug; 5(1):785. PubMed ID: 35927436
[TBL] [Abstract][Full Text] [Related]
12. New Perspectives on Ebola Virus Evolution.
Brown CJ; Quates CJ; Mirabzadeh CA; Miller CR; Wichman HA; Miura TA; Ytreberg FM
PLoS One; 2016; 11(8):e0160410. PubMed ID: 27479005
[TBL] [Abstract][Full Text] [Related]
13. The signal peptide of the ebolavirus glycoprotein influences interaction with the cellular lectins DC-SIGN and DC-SIGNR.
Marzi A; Akhavan A; Simmons G; Gramberg T; Hofmann H; Bates P; Lingappa VR; Pöhlmann S
J Virol; 2006 Jul; 80(13):6305-17. PubMed ID: 16775318
[TBL] [Abstract][Full Text] [Related]
14. Antigenic subversion: a novel mechanism of host immune evasion by Ebola virus.
Mohan GS; Li W; Ye L; Compans RW; Yang C
PLoS Pathog; 2012; 8(12):e1003065. PubMed ID: 23271969
[TBL] [Abstract][Full Text] [Related]
15. The Ebola-Glycoprotein Modulates the Function of Natural Killer Cells.
Edri A; Shemesh A; Iraqi M; Matalon O; Brusilovsky M; Hadad U; Radinsky O; Gershoni-Yahalom O; Dye JM; Mandelboim O; Barda-Saad M; Lobel L; Porgador A
Front Immunol; 2018; 9():1428. PubMed ID: 30013549
[TBL] [Abstract][Full Text] [Related]
16. Matrix-M adjuvant enhances antibody, cellular and protective immune responses of a Zaire Ebola/Makona virus glycoprotein (GP) nanoparticle vaccine in mice.
Bengtsson KL; Song H; Stertman L; Liu Y; Flyer DC; Massare MJ; Xu RH; Zhou B; Lu H; Kwilas SA; Hahn TJ; Kpamegan E; Hooper J; Carrion R; Glenn G; Smith G
Vaccine; 2016 Apr; 34(16):1927-35. PubMed ID: 26921779
[TBL] [Abstract][Full Text] [Related]
17. Ebolavirus Glycoprotein Fc Fusion Protein Protects Guinea Pigs against Lethal Challenge.
Konduru K; Shurtleff AC; Bradfute SB; Nakamura S; Bavari S; Kaplan G
PLoS One; 2016; 11(9):e0162446. PubMed ID: 27622456
[TBL] [Abstract][Full Text] [Related]
18. The Roles of Ebola Virus Soluble Glycoprotein in Replication, Pathogenesis, and Countermeasure Development.
Zhu W; Banadyga L; Emeterio K; Wong G; Qiu X
Viruses; 2019 Oct; 11(11):. PubMed ID: 31683550
[TBL] [Abstract][Full Text] [Related]
19. Distinct Immunogenicity and Efficacy of Poxvirus-Based Vaccine Candidates against Ebola Virus Expressing GP and VP40 Proteins.
Lázaro-Frías A; Gómez-Medina S; Sánchez-Sampedro L; Ljungberg K; Ustav M; Liljeström P; Muñoz-Fontela C; Esteban M; García-Arriaza J
J Virol; 2018 Jun; 92(11):. PubMed ID: 29514907
[No Abstract] [Full Text] [Related]
20. Impact of Ebola mucin-like domain on antiglycoprotein antibody responses induced by Ebola virus-like particles.
Martinez O; Tantral L; Mulherkar N; Chandran K; Basler CF
J Infect Dis; 2011 Nov; 204 Suppl 3(Suppl 3):S825-32. PubMed ID: 21987758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
